Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CS5001 |
Synonyms | |
Therapy Description |
CS5001 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting ROR1 linked to DNA-crosslinking agent, which potentially inhibits tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr LBA008). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CS5001 | CS-5001|CS 5001|LCB 71|LCB-71|LCB71|ABL 202|ABL-202|ABL202 | ROR1 Antibody 7 | CS5001 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody targeting ROR1 linked to DNA-crosslinking agent, which potentially inhibits tumor growth (Mol Cancer Ther 2021;20(12 Suppl):Abstract nr LBA008). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05279300 | Phase I | CS5001 | A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | AUS | 1 |